Levels of Amyloid Beta-42, Interleukin-6 and Tumor Necrosis Factor-Alpha in Alzheimer’s Disease and Vascular Dementia

被引:0
作者
Sema Uslu
Zubeyde Eken Akarkarasu
Demet Ozbabalik
Serhat Ozkan
Omer Çolak
Emine Sutken Demirkan
Ayşe Ozkiris
Canan Demirustu
Ozkan Alatas
机构
[1] University of Eskişehir Osmangazi,Department of Medical Biochemistry, School of Medicine
[2] University of Eskişehir Osmangazi,Department of Neurology, School of Medicine
[3] University of Eskişehir Osmangazi,Department of Biostatistics, School of Medicine
来源
Neurochemical Research | 2012年 / 37卷
关键词
Alzheimer’s disease; Amyloid β42; Interleukin-6; TNF-α; Vascular dementia;
D O I
暂无
中图分类号
学科分类号
摘要
Amyloid β42 (Aβ42) and proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD) and vascular dementia (VaD). Our aim was to examine whether the changes in these parameters would be able to discriminate the patients with AD from those with VaD and from healthy individuals. We have analyzed the levels of Aβ42, IL-6 and TNF-α in the serum of newly diagnosed 28 AD patients, 16 VaD patients and 26 healthy non-demented controls. We also investigated whether there is an association between Aβ42, IL-6 and TNF-α levels and mini-mental state examination (MMSE) scores and body mass indexes (BMI) of patients. Our data showed a significant decrease in serum Aβ-42 levels in AD patients compared to VaD patients and controls. Levels of IL-6 and TNF-α were not different between AD patients, VaD patients and controls. We observed a correlation between Aβ-42 levels and MMSE scores and BMI levels in both AD and VaD patients. However, Aβ-42 levels were not correlated with IL-6 and TNF-α levels. Significantly lower levels of Aβ42 found in the serum of AD patients than that of VaD patients and controls suggests that it can be a specific biochemical marker for AD.
引用
收藏
页码:1554 / 1559
页数:5
相关论文
共 126 条
  • [1] Lee YJ(2010)Inflammation and alzheimer’s disease Arch Pharm Res 33 1539-1556
  • [2] Han SB(2011)Pharmacotherapy and prevention of vascular dementia CNS Neurol Disord Drug Targets 10 370-390
  • [3] Nam SY(2009)Prevalence of dementia and associated risk factors in Middle Anatolia, Turkey J Clin Neurosci 16 1455-1459
  • [4] Moretti A(1984)Clinical diagnosis of alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer’s disease Neurology 34 939-944
  • [5] Gorini A(1993)Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international workshop Neurology 43 250-260
  • [6] Villa RF(2008)Plasma biomarkers of alzheimer’s disease Curr Opin Psychiatry 21 260-267
  • [7] Arslantaş D(2005)The role of inflammation in alzheimer’s disease Int J Biochem Cell Biol 37 289-305
  • [8] Ozbabalik D(2010)Neuroinflammatory processes in alzheimer’s disease J Neural Transm 117 919-947
  • [9] Metintaş S(2002)Biochemical markers related to alzheimer’s dementia in serum and cerebrospinal fluid Neurobiol Aging 23 485-508
  • [10] McKhann G(2006)Circulating biomarkers of cognitive decline and dementia Clin Chim Acta 364 91-112